After patient deaths, InVivo slashes staff and ousts science chief

One month after disclosing that a third patient had died in a trial of its experimental spinal cord injury treatment, Cambridge-based InVivo Therapeutics said it plans to lay off more than a third of its workforce and terminate its chief scientific officer. InVivo (Nasdaq: NVIV) announced the restructuring in a release on Monday, saying that it will cut 13 of its 33 employees. In a separate federal filing, the company said it had notified its chief scientific officer, Thomas Ulich, that he will…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news